OncLive TV

Martin Dreyling, MD, discusses the key safety data from the phase 3 TRIANGLE trial in younger patients with mantle cell lymphoma.

Ricardo Costa, MD, MSC, discusses the implications of the phase 3 KEYNOTE-522 trial trial in patients with high-risk, early-stage triple-negative breast cancer.

Atish D. Choudhury, MD, PhD, discusses the need for expanded genomic profiling and additional biomarkers to better predict which patients with metastatic castration-resistant prostate cancer could benefit from treatment with PARP inhibitor–based combinations.

Akash Mukherjee, MD, discusses the importance of understanding disease biology when attempting to individualize treatment approaches in mantle cell lymphoma.

Brian I. Rini, MD, FASCO, discusses the current treatment landscape for patients with relapsed/refractory renal cell carcinoma.

Stephanie A. Berg, DO, discusses key ongoing trials in metastatic urothelial carcinoma.

Sagar Patel, MD, discusses complications following allogeneic stem cell transplant that can occur in patients with myelofibrosis.

Tycel Phillips, MD, MPH, discusses the key implications of investigating glofitamab monotherapy in patients with relapsed/refractory mantle cell lymphoma.

Vikas Kumar Singh, MD, discusses the potential benefit of the combination of enfortumab vedotin plus pembrolizumab for the treatment of patients with locally advanced or metastatic urothelial cancer who are not eligible to receive cisplatin-containing chemotherapy.

Ryan Fecteau, MD, PhD, discusses the benefit of utilizing a multidisciplinary approach in bladder and prostate cancers.

Tae Kon Kim, MD, PhD, discusses key results on the synergistic effects of PD-1H blockade in acute myeloid leukemia..

Andre H. Goy, MD, discusses key findings from an assessment of durable responses in the phase 2 ZUMA-2 trial in relapsed/refractory mantle cell lymphoma.

Michael C. Haffner, MD, PhD, explains the genomic differences between prostate adenocarcinoma of the prostate and prostatic basal cell carcinoma, an extremely rare disease.

Kyle A. Blum, MD, MS, says that results from a study of patients renal medullary carcinoma suggest that with CA-125, an established biomarker for ovarian cancer, may play a similar role in this rare disease.

Kyle A. Blum, MD, MS, says that patients with renal medullary carcinoma have poor prognosis, but anecdotal evidence suggests that survival outcomes may be improving.

Kyle A. Blum, MD, MS, discusses how few physicians have experience with renal medullary carcinoma, and the disease often presents with nonspecific symptoms.

Kyle A. Blum, MD, MS, explains how renal medullary cancer, like most rare cancers, can be difficult to study. However, there are several ongoing studies that include this patient population.

Ilyas Sahin, MD, discusses the background and findings of the phase 2 IMbrave 151 trial in advanced biliary tract cancer.

Daniel Walden, MD, discusses the association of low expression of RNA of wild-type homologous recombination genes and survival in colorectal cancer.

Shai Friedland, MD, discusses a multimodal screening blood test for advanced adenomas in colorectal cancer.

Rutika Mehta, MD, MPH, discusses which patients with esophageal squamous cell carcinoma may benefit most from the different frontline treatment options available and highlights key treatment developments with adjuvant immunotherapy plus chemotherapy.

Sherise Rogers, MD, MPH, discusses the potential of utilizing circulating tumor DNA to help guide second-line treatment decisions in patients with metastatic colorectal cancer.

Alberto Montero, MD, MBA, CPHQ, discusses the significance of the FDA approval of elacestrant in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer.

Seth Wander, MD, PhD, discusses the investigation of resistance to CDK4/6 inhibitors and the role of NF1 mutations in breast cancer.

Patrick Neven, MD, discusses the association between cell cycle–related genes and outcomes for patients with hormone receptor–positive/HER2-negative advanced breast cancer treated on the phase 3 MONALEESA-2, MONALEESA-3, and MONALEESA-7 trials.

Yuliya Linhares, MD, discusses the trial design, methodology, and key efficacy and safety results from the phase 2 OUTREACH trial (NCT03744676) evaluating lisocabtagene maraleucel (liso-cel; Breyanzi) in relapsed/refractory large B-Cell lymphoma (LBCL).

Vaagn Andikyan, MD, discusses the utilization of hyperthermic intraperitoneal chemotherapy in patients with stage III epithelial ovarian cancer.

Ariel Perez Perez, MD, discusses key results and clinical implications from a retrospective study of polatuzumab-vedotin plus rituximab with or without bendamustine in relapsed/refractory large B-cell lymphomas.

Rohit Kumar, MD, discusses the benefits of combining immunotherapy agents with each other or with TKIs in patients with renal cell carcinoma and the unmet needs that remain for patients with RCC who do not respond to immunotherapy.

Vikas Kumar Singh, MD, discusses findings from the phase 3 GETUG-AFU V05 VESPER (NCT01812369) and JAVELIN Bladder 100 (NCT02603432) trials in patients with bladder cancer.